Ibex Medical Analytics, a leader in AI-powered pathology, has announced a strategic leadership transition alongside the expansion of its life sciences platform. The company is positioning its technology as a core component of cancer drug development, from early-stage biomarker assessment to clinical trial optimization and regulatory approval.
Key executive appointments include:
-
New Chief Executive Officer: Yair Heller, formerly the COO, has been promoted to CEO to lead the global scaling of the Ibex platform.
-
Head of Biopharma Division: Co-founder Joseph Mossel will now focus on the biopharma sector and oversee clinical growth initiatives within the United States.
The transition follows a period of rapid commercial growth in 2025, during which Ibex doubled its case volume for the second consecutive year and increased its customer base by 70%. The company successfully implemented its AI tools across major laboratory networks in Europe and the U.S., including partnerships with Fimlab and PathGroup. Moving forward, Ibex intends to deepen its involvement in the pharmaceutical lifecycle, providing pathologists and researchers with high-precision tools to enhance the accuracy of cancer diagnostics and treatment development.